Coronary Physiology Is Useful in Chronic Kidney Disease

Coronary physiology, FFR and iFR, has been shown safe to defer lesions and effective to save stents by different randomized studies and registries. However, patients with chronic kidney disease have not been thoroughly analyzed yet, which brings us to the question about what to do in the face of their negative evolution, when atherosclerosis develops faster, and stress tests are required before we would normally expect.

taller de imágenes y fisiología intracoronaria

This is a retrospective study including 439 patients. 319 (72.7%) presented conserved kidney function assessed with glomerular filtration (eGFR > 60 mL/min/1.73 m2,), and 120 showed evidence of chronic kidney disease (CKD) (glomerular filtration eGFR < 60 mL/min/1.73 m2).

251 patients with conserved kidney function were deferred with FFR (78,7%) and 78 with iFR (21,3%), while 94 CKD patients were deferred with FFR (78,3%) and 26 with iFR (21,7%).

Primary end point was a composite of all cause death, MI or unplanned revascularization. Secondary end point was all cause death, cardiac death, MI and unplanned revascularization. 

Patients with CKD were older, and presented more hypertension, diabetes, peripheral vascular disease and use of anticoagulation, but lower use of ASA. 

Read also: Tricuspid Regurgitation: Edge-to-Edge Treatment with PASCAL.

There were no differences in number of interrogated lesions or their location. The left anterior descending artery was the most involved. 

FFR was used 80% of times.

After 4 years, primary end point was higher in patients with CKD (25% vs. 14% p=0.01). Also, all-cause mortality (13.3% vs. 5.3%, p=0.006) and cardiovascular mortality (5.8% vs. 1.3% p=0.01) were higher. Unplanned revascularization was also higher, though not significantly. There were no differences in MI or target vessel related MI. 

Read also: Progress-CTO Score: A Key New Tool to Plan CTO.

Patients with 4 or 5 stage CKD presented more events vs. patients with conserved kidney function.

Evolution was analyzed according to lesion assessment strategy and there were no differences between FFR and iFR.

Conclusion

Patients with CKD and deferred coronary lesions after pressure-wire evaluation develop more events in the long term compared against patients presenting conserved kidney function. However, this increased number of events in CDK patients was rarely related to the deferred vessel, which suggests an epiphenomenon of intrinsically higher cardiovascular risk in CKD patients.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Safety of coronary revascularization deferral based on fractional flow reserve and instantaneous wave-free ratio in patients with chronic kidney disease.

Reference: Alejandro Travieso, et al. Cardiol J 2022, 29, 4: 553–562.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...